DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
USP24 is a cross-reactive DUB targeting MOV10 to regulate IFN-I production
The type I Interferon (IFN-I)-induced ubiquitin-like modifier Interferon-Stimulated Gene 15 (ISG15) plays a crucial role in the innate immune response against viral infections. ISG15 is conjugated to target proteins by an enzymatic cascade, called ISGylation. While ubiquitin-specific protease 18 (USP18) serves as the major deISGylase counteracting ISG15 conjugation, ISG15 cross-reactive deubiquitylating enzymes (DUBs) have also been reported. Here, we identify USP24 as an ISG15 cross-reactive DUB through activity-based protein profiling. USP24 processes pro-ISG15 and ISG15-linked substrates in vitro, and its depletion increases ISG15 conjugates following interferon stimulation in cells without altering canonical IFN-I signaling. USP24 knockout cells show increased IFN-β and ISG expression upon activation of cytosolic RNA sensing via viral mimicry. Proteomic analysis identifies RNA helicase Moloney leukemia virus 10 (MOV10) as a specific target of USP24 for deISGylation. Our data revealed that ISGylation of MOV10 promotes MOV10 interaction with IFIT3 and enhances IFN-β production/secretion in response to viral stimuli. This process is negatively regulated by USP24, which directly deISGylates MOV10. Our data highlight USP24's role in modulating ISGylation and IFN-I production, suggesting USP24 as a potential therapeutic agent for infectious and inflammatory diseases., This work was supported by the TRIM-NET project, which received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 813599. A.S was supported by ICI00026 from the NWO Gravity Program. S.D., A.P.F., and B.M.K. were supported by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China [grant number: 2018-I2M-2-002] and by Pfizer. Work in the A.P.F. lab was funded by Ono Pharma UK Ltd. S.Z. was supported by the Government of Spain (PID2022-140328OB-I00, MCIN/AEI/10.13039/501100011033/FEDER, UE). M.G. received a contract from Comunidad de Madrid (PIPF-2022/SAL-GL-24549). K.P.K. received funding from the German Research Foundation (DFG), Project ID DFG 423813989/GRK2606, and under Germany’s Excellence Strategy (CIBSS–EXC-2189–Project ID 390939984). T.O. and A.G.V.D.V. were supported by a research grant from the Institute for Chemical Immunology (ICI-00203 and ICI-00046), which is funded by a Gravitation project (024.002.009) from the Dutch Research Council (NWO), a VIDI research grant (09150171910070), and an Aspasia award (015.015.046) from the NWO, and the LUMC., Peer reviewed
Proyecto:
EC / H2020 813599
,
AEI / Proyectos de I+D+i PID2022-140328OB-I00
,
Comunidad de Madrid / PIPF-2022 SAL-GL-24549
DOI: http://hdl.handle.net/10261/446825, https://api.elsevier.com/content/abstract/scopus_id/105046473835
HANDLE: http://hdl.handle.net/10261/446825, https://api.elsevier.com/content/abstract/scopus_id/105046473835